Compounds > triazoles
Page last updated: 2024-08-24

triazoles and ponatinib

triazoles has been researched along with ponatinib in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bhalla, KN; Bradner, JE; Devaraj, SG; Fiskus, W; Iyer, S; Leveque, C; Portier, BP; Qi, J; Shah, B; Sharma, S1
Brill, B; Chilov, G; Haberbosch, I; Hoelzer, D; Metodieva, A; Mian, AA; Novikov, F; Ottmann, OG; Rafiei, A; Ruthardt, M; Stroganov, O; Stroylov, V; Titov, I; Zeifman, A1
Bae, E; Gu, YK; Hirao, A; Ishihara, K; Jeong, ES; Jin, CH; Jomen, Y; Kim, DH; Kim, DK; Kim, DW; Kim, SJ; Krause, DS; Li, S; Naka, K; Ooshima, A; Oshima, H; Oshima, M; Sheen, YY; Takihara, Y1
Ben-Batalla, I; Bokemeyer, C; Brümmendorf, TH; Carmeliet, P; Clark, RE; Erdmann, R; Ernst, T; Helgason, GV; Hochhaus, A; Holyoake, TL; Jørgensen, H; Koschmieder, S; Loges, S; Mitchell, R; Mitra, S; Pantel, K; Rankin, S; Schafhausen, P; Schultze, A; Vandenberghe, P; Velthaus, JL; von Amsberg, G1

Other Studies

4 other study(ies) available for triazoles and ponatinib

ArticleYear
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:10

    Topics: Animals; Apoptosis; Azepines; Cell Cycle Proteins; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Mice; Nuclear Proteins; Pyridazines; Signal Transduction; Transcription Factors; Triazoles; Vascular Endothelial Growth Factor Receptor-1

2014
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
    Leukemia, 2015, Volume: 29, Issue:5

    Topics: Animals; Antigens, Ly; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Female; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Humans; Imidazoles; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Mice; Mice, Inbred C57BL; Models, Molecular; Mutagenesis; Mutation; Point Mutation; Proto-Oncogene Proteins c-kit; Pyridazines; Pyridines; Translocation, Genetic; Triazoles; Xenograft Model Antitumor Assays

2015
Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells.
    Cancer science, 2016, Volume: 107, Issue:2

    Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Disease Models, Animal; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridazines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Transfection; Transforming Growth Factor beta; Triazoles

2016
Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, May-01, Volume: 23, Issue:9

    Topics: Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyridazines; Receptor Protein-Tyrosine Kinases; Small Molecule Libraries; Triazoles

2017